Apolipoproteins as predictive markers of metabolic-vascular risk in pediatrics

Authors

Keywords:

metabolic-vascular risk, risk predictor markers, apolipoproteins, cardiometabolic disease.

Abstract

Introduction: The search for new predictive markers, in the stratification of metabolic-vascular risks, is of vital importance in the prevention, diagnosis and timely treatment of cardiometabolic diseases, considering that the atherosclerotic process begins in childhood. The documentary review was carried out between March and July 2022, consulting the PubMed/Medline, SciElo, Scopus and Google Scholar databases as a gateway to information on the topic. 33 original articles were reviewed in the period 2012-2021 in English and Spanish, 29 were referenced and the key terms for the search were, metabolic-vascular risk, apolipoproteins A1 and B100, markers predictive of metabolic-vascular risk, childhood adolescence.
Objective: To analyze the importance of apolipoproteins as predictive markers of pediatric metabolic-vascular risk.
Development: Apolipoproteins have emerged as a very viable alternative, particularly the determination of ApoB 100 and ApoA 1, which express the balance between atherogenic and antiatherogenic activity and are present from the early ages of life. Early diagnosis of these markers will allow for early interventions to promote changes to healthy lifestyles, as well as preventive treatments that prevent complications of cardiometabolic disease.
Conclusions: Considering that the atherosclerotic process begins at an early age, apolipoproteins constitute markers in the prediction of metabolic-vascular risk, their determination allows the identification, risk stratification and proposal of preventive strategies from pediatric ages.

Downloads

Download data is not yet available.

Author Biographies

Jenrry Alvarez Cruz, Hospital Dr. Luis Díaz Soto

Servicio de Pediatría

Liuba Luisa Arteche Hidalgo, Universidad de Ciencias Médicas de las FAR

Formación Académica de Posgrado

Doctor en CienciaMédico especialista de SugundoGrado en MGI.

Máster en Salud Ambiental y en Educación Médica.

Investigadora AUxiliar. Profesora Titular.

Amaya Blanco del Frade, Hospital Pediátrico Docente “Juan Manuel Márquez”

Pediatría

Mara Carassou Gutiérez, Hospital Dr. Luis Díaz Soto

Servicio pediatría

Yanet Romero Reinaldo, Hospital Dr. Luis Díaz Soto

Pediatría

Clara Ligia Santamaría Trujillo, Hospital Dr. Luis Díaz Soto

Departamento de Ciencia y técnica

References

1. de Lima MN., da Silva DA., Kruze AI. Apolipoproteins and their association with cardiometabolic risk biomarkers in adolescents. Nutr. Hosp. 2015 [acceso: 09/06/2022]; 32(6):2674-83. Disponible en: http://scielo.isciii.es/scielo.Php?Script=sci-arttext&pid=S0212-1611201500120004 2&lng=es

2. Qayum O, Alshami N, Ibezim CF, Reid KJ, Noel-MacDonnell JR, Raghuveer G. Lipoprotein (a): Examination of Cardiovascular Risk in a Pediatric Referral Population. Pediatr Cardiol. 2018; 39(8):1540-1546. DOI: 10.1007/s00246-018-1927-3.

3. Morita S. Metabolism and modification of apolipoprotein B-containing lipoproteins involved in dyslipidemia and atherosclerosis. Toro Biol Pharm. 2016 [acceso: 09/07/2022];39(1):1-24. Disponible en: https://www.jstage.jst.go.jp/article/bpb/39/1/39_b15-00716/article/-char/ja/

4. Fernández Friera L, Fuster V, López Melgar B, Oliva B, García Ruiz JM, Mendiguren J, et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. JACC. 2017[acceso: 08/06/2022]; 70:2979-91. Disponible en: https://www.Sciencedirect.com/science/article/pii/S07351097174 12320

5. Bonilla-Bagnarello Y, Holst-Schumacher I, Barrantes-Santamaría M, Alvarado-Ulate P, Marchena-Angulo J, Molina-Escobar M. Niveles séricos de lipoproteína (a), apolipoproteínas A1 y B100 y otros factores de riesgo cardiovascular en una población de adultos del área urbana de San José, Costa Rica. Costarr Cardiol. 2013 [acceso: 19/04/2022]; 15(2):7-14. Disponible en: https://www.scielo.sa.cr/pdf/rcc/v15n2/art02v15n2.pdf

6. Sapunar J, Aguilar Farias N, Navarro J, Araneda G, Chandía- Poblete D, Manríquez V, et al. Alta prevalencia de dislipidemias y riesgo aterogénico en una población infanto-juvenil. Rev. Med. Chile. 2018 [acceso: 25/11/2022]; 146(10):1112-22. Disponible en: https://scielo.conocyt.cl/scielo.php?script=sci.arttext&pid=S003498872018001001112&lng=es

7. Bodde MC, Hermans MPJ, Jukema JW, Schalij MJ, Lijfering WM, Rosendaal FR, et al. Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clin Res Cardiol. 2019;108(5):520-38. DOI: 10.1007/s00392-018-1381-5

8. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020 [acceso: 25/06/2022]; 16;382(3):244-55. Disponible en: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1905239?articleTools=true

9. Noreña-Peña A, García de las Bayonas López P, Sospedra López I, Martínez-Sanz JM, Martínez-Martínez G. Dislipidemias en niños y adolescentes: factores determinantes y recomendaciones para su diagnóstico y manejo. Rev Esp Nutr Hum Diet. 2018 [acceso: 25/06/2022]; 22(1):72-91. Disponible en: https://scielo.isciii.es/pdf/renhyd /v22n1/2174-5145-renhyd-22-01-72.pdf

10. Arroyo Díez FJ, Romero Albillos JA, López Valero GN. Dislipemias en edad pediátrica. Protoc diagn ter pediatr. 2019 [acceso: 25/11/2022]; 1:125-40. Disponible en: https://www.aeped .es /sites/default/files/documentos/08dislipemias.pdf

11.III Consenso Nacional para el Manejo del Paciente con Dislipidemia. Manejo integral de las dislipidemias en niños, niñas y adolescentes. Avances Cardiol 2014 [acceso: 25/11/2022];34(1):90-98. Disponible en: https://www.analesdenutricion.Org.ve/publicaciones/192.pdf

12. Cuartas S; Pérez Torre ME. Alteraciones lipídicas y estrati?cación del riesgo cardiometabólico en niños con obesidad menores de 10 años. Revista Argentina de Lípidos. 2021 [acceso: 25/11/2022]; 5(3): [aprox.9p.]. Disponible en: http://portal.amelica. org/ameli/journal/450/4502821002/html/

13. Manzur M, Rodríguez S, Yáñez S, Ortuño M, García S, Fernández N, et al. Síndrome metabólico, factores de riesgo en niños y adolescentes con sobrepeso. Gac Med Bol. 2016 [acceso: 25/11/2022]; 39(2):94-8. Disponible en: http://www.scielo.org.bo/pdf/gmb/ v39n2/v39n2a8.pdf

14. Sánchez Belkis V, García K, González Hermida A, Saura Naranjo CE. Sobrepeso y obesidad en niños de 5 a 12 años. Rev. Finlay 2017 [acceso: 25/11/2022]; 7(1):47-53. Disponible en: https://revfinlay.sld.cu/index.php/finlay/article/view/445

15. De Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, et al. Reducción del riesgo cardiovascular en pacientes pediátricos de alto riesgo: una declaración científica de la asociación americana del corazón. Circulación. 2019 [acceso: 25/11/2022];139(13): e603-34. Disponible en: https://doi.org/10.1161/CIR.0000000000000618

16. Falke GO, Pellegrino JA. Salud integral del joven y del adolescente. Medicina preventiva y social. Rev de la Asociación Médica Argentina. 2020 [acceso: 25/06/2022];133(4):24-9. Disponible en: https://ama-med.org.ar/uploads-archivos/2022/Rev-4-2020pag-24-29Falke.pdf

17. Llapur Milián R, González Sánchez R. La enfermedad cardiovascular aterosclerótica desde la niñez a la adultez. Rev Cubana Pediatr. 2017 [acceso: 25/06/2022];89(3):1-6. Disponible en: http://scielo.sld.cu/scielo.php?script=sciabstract&pid=S003475312017000300001&ln=es&nrm=iso&tlng=es

18. Vicente Sánchez B, García K, González Hermida A, Saura Naranjo C E. Sobrepeso y obesidad en niños de 5 a 12 años. Rev Finlay. 2017 [acceso: 30/09/2023]; 7(1):1-7. Disponible en: http://scielo.sld.cu/pdf/rf/v7n1 /rf07107.pdf

19. Aghayan M, Asghari G, Yuzbashian E, Dehghan P, Khadem H, Mirmiran P, et al. Association of nuts and unhealthy snacks with subclinical atherosclerosis among children and adolescents with overweight and obesity. Nutr Metab (Lond). 2019 [acceso: 25/06/2022]; 2(1):1-16. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C6454780/

20. Pires A, Sena C, Seiça R. Dyslipidemia and cardiovascular changes in children. Current Opinion in Cardiol. 2016; 31(1):95-100.DOI:10.1097/HCO.0000000000000249

21. Candelino M, Tagi VM, Chiarelli F. Cardiovascular risk in children: a burden for future generations. Ital J Pediatr. 2022; 48:57. DOI: 10.1186/s13052-022-01250-5

22. Merino González CR. Impacto de la cuantificación de la ApoA 1 y B en niños y adolescentes con historia familiar de enfermedad cardiovascular precoz [Tesis de Maestría]. Chile: Universidad Concepcion; 2018. [acceso: 25/06/2022]. Disponible en: http://repositorio.udec.cl/jspui/bitstream/11594/2864/4/Tesis_Impacto_de_la_cuantificacion_de_las_apoliproteinas.pdf

23. Pereira Castro AP, Miranda Hermsdorff HH, Cupertino Milagres LC, Martins de Albuquerque FM, de Santis Filgueiras M, Pereira Rocha NP, et al. Increased ApoB/ApoA1 ratio is associated with excess weight, body adiposity, and altered lipid profile in children. J Pediatr. 2019 [acceso: 25/06/2022]; 95 :238-46. Disponible en: https://www.scielo.br/j/jped/a/h9XPSDDzC3K4BqYTvVBJqhy/?format=pdf&lang=en

24. Rocha Chamorro AC, Moscoso Gama JM. Síndrome metabólico en niños y adolescentes. Biociencias (UNAD). 2017 [acceso: 25/06/2022]1(1):59-69. Disponible en: https://hemeroteca.unad.edu.co/index.php/Biociencias/article/view/2221/2381

25. Varona Pérez P, Armas N, Suárez Medina D, Dueñas Herrera A, Gámez Sánchez D, Ortega Torres YY. Niveles plasmáticos de la razón Apolipoproteína B/A1 y riesgo cardiovascular en la población cubana. Revista Cubana de Cirugía Cardiovascular. 2018 [acceso: 09/09/2021]; 24(3):1-12. Disponible en: https://www.google.com/search?client=firefox-b-d&q=https%3A%2F%2Fwww.sciencedirect.Com+%2Fscience%2Farticle%2Fpii%2FS0021755717306812%3Fvia%253Dihub

26. Pereira Vizentin N, Santos Cardoso PM, Gomes Maia CA, Perez Alves I, Lunardi Aranha G, Tabares Giannini D. Dyslipidemia in Adolescents Seen in a University Hospital in the city of Rio de Janeiro/Brazil: Prevalence and Association. Arq Bras Cardiol. 2019 [acceso: 25/05/2022];112(2):147-51. Disponible en: https://www.scielo.br/j/abc/a/tHX8tGGMs854jmDCfKr7y6d/?format=pdf&lang=en

27. Wang K, Shan S, Zheng H, Zhao X, Chen C, Liu C. Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study. Lipids Health Dis. 2018 [acceso: 25/05/2022];17(1):196. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104008/

28. Gambetta JC, Araujo MB, Chiesa P. Dislipemias en la edad pediátrica. Importancia del diagnóstico y tratamiento precoces. Rev Urug. Cardiol. 2019 [acceso: 25/06/2022]; 34(3):313-23. Disponible en:http://www.scielo.edu.uy/pdf/ruc/v34n3/1688-0420-ruc-34-03-208.pdf

29. De la Torre Cisneros K. Utilidad clínica de los índices aterogénicos para la valoración del riesgo cardiovascular: un enfoque desde el laboratorio clínico. Rev Dom. Cien. 2019 [acceso: 25/05/2022]; 5(3):57-70. Disponible en: https://dialnet.unirroja.es/servlet/articulo?Código=7154289

Downloads

Published

2023-11-08

How to Cite

1.
Alvarez Cruz J, Arteche Hidalgo LL, Blanco del Frade A, Carassou Gutiérez M, Romero Reinaldo Y, Santamaría Trujillo CL. Apolipoproteins as predictive markers of metabolic-vascular risk in pediatrics. Rev Cubana Med Milit [Internet]. 2023 Nov. 8 [cited 2025 Apr. 19];52(4):e02302742. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/2742

Issue

Vol. 52 No. 4 (2023): October - december

Section

Review Article

License

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.